Early Complications after Lung Resections at Patients Treated For Lung Cancer with and Without Neoadjuvant Hemiotheraphy

Goran Kondov¹, Simonida Crvenova², Zoran Spirovski¹, Trajanka Trajkovska¹, Sashko JOvev¹, Irena Kondova-Topuzovska⁴, Natasha Tolevska¹, Borislav Kondov¹

¹University Clinic for Thoracic Surgery, Medical Faculty, University "Ss Cyril and Methodis", Skopje, Republic of Macedonija; ²University Clinic for Oncology, Medical Faculty, University "Ss Cyril and Methodis", Skopje, Republic of Macedonija; ³University Clinic for Anesthesiology and Reanimatology, Medical Faculty, University "Ss Cyril and Methodis", Skopje, Republic of Macedonija; ⁴University Clinic for Infective Disease and Febrile Conditions, Medical Faculty, University "Ss Cyril and Methodis", Skopje, Republic of Macedonija


Key words: NSLC; neoadjuvant chemotherapy; lung resection; complications; only lung resection.

Correspondence: Prof. dr Goran Kondov MD, PhD. University Clinic for Thoracic and Vascular Surgery, Medical Faculty, Vodopjańska 17, 1109 Skopje, Republic of Macedonija. E-mail: kondov@yahoo.com

Received: 03-Nov-2011; Revised: 12-Dec-2011; Accepted: 22-Feb-2012; Online First: 12-Jun-2012

Abstract

Background: Anatomical lung resection offers the best chance of cure for patients with localized lung cancer. Very often late diagnoses, advanced stage of the disease limit radical anatomical surgical resection. Use of neoadjuvant chemotherapy made some of the cases operable, and later they were surgically treated.

Aim: to evaluate early (surgical) complications at patients with neoadjuvant therapy.

Material and Methods: We compare 36 patients surgically treated with lung resection, before treated with neoadjuvant chemotherapy (3 to 6 cycles with platinum based regiments under protocol) with 42 patients surgically treated without neoadjuvant chemotherapy, in the same period, in the 2009 and 2010.

Results: At the group with neoadjuvant chemotherapy we register more intraoperative and early postoperative complications as: bleeding 10 vs. 7, p=0.63, changes in lung vessels 3 vs. 0, p=0.8, prolonged air leak 9 vs. 6, p=0.63, stump fistula (at pneumectomy patients) 2 vs. 0, p=0.76, pneumonia 9 vs. 3, p=0.86, wound infection 2 vs 0, p=0.73, atelectasis 8 vs. 2, p=0.88, prolonged pleural drainage 10 vs. 4, p=0.87. There, also, was no difference in 30 days mortality rate between groups.

Conclusions: Neoadjuvant therapy increased the perioperative complications in this group of patients compared with a similar group undergoing anatomical lung resection in the same institution. The most common complication in patients receiving induction chemotherapy was detected at the group with neoadjuvant chemotherapy. Strategies to prevent these complications will be important, especially if chemotherapy before resection becomes the standard for all patients with non–small cell lung cancer.

Introduction

Radical anatomical resection of the lung (lobectomy or pneumectomy) for the early stage of NSCLC is method of choice in the treatment [1]. Unfortunately only 10 to 20% of patients with newly diagnosed lung carcinoma at the end become candidate for lung resection [2].

Use of neoadjuvant hemiotheraphy made some of the cases operable, and later they were surgically treated. Pre-operative (neo-adjuvant) chemotherapy has shown promise in small trials restricted to stage IIIA patients [3-5]. In last time there were many study to use neoadjuvant hemiotheraphy for IB, IIA and IIB stage also [6-12]. However, little is known about the effect of preoperative chemotherapy on surgical stress and postoperative complications associated with surgical intervention.

The aim of this study is to evaluate early (surgical)
complications at patients with and without neoadjuvant chemotherapy.

Material and Methods

We compare 36 patients surgically treated with lung resection, before treated with neoadjuvant therapy (3 to 6 cycles platinum based chemotherapy by protocol, giving combination of cisplatin and gemcitabin or ciclofosfamid or taxol) with 42 patients surgically treated without neoadjuvant chemotherapy, in the same period, in the 2009 and 2010. All patients with neoadjuvant chemotherapy received 3-6 cycles of chemotherapy. Patients with downstage were treated surgically. Surgery (lung resection—“wedge excision”, lobectomy or pneumectomy) were done 3 to 5 weeks after last chemotherapy. Other patients with progress of the disease were further treated with chemo-radiotherapy. Stage of the lung cancer disease were done using VII revised TNM classification, from 2009.

Basic characteristic of the groups were shown on Table 1.

Table 1: Characteristics of groups which were evaluated.

<table>
<thead>
<tr>
<th>Neoadjuvant Surgery</th>
<th>After neoadjuvant therapy</th>
<th>Candidate for surgery</th>
<th>Surgically treated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tobacco consumer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histological type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Location</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgical intervention</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Results

Neoadjuvant chemotherapy was used at 34% patients that were surgically treated at our Clinic. From 100 patients, which were in IIA, IIB, IIIA and IIIB stage that have no contraindications for surgery, that were send to neoadjuvant chemotherapy, at 28% there were progress of the disease so we lost them for surgery and they were further with chemo-radiotherapy. Twenty four % of patients stay at same stage, and some of them were candidate for surgery, especially if the starting stage is II, and if there were no other contraindications from cardiac and lung status. At 48 % were detected down staging, and all this patients were candidate for surgical resection if there were no detected other contraindication. Finally from all this patients surgically were treated only 36 (Table 2).

At the group with neoadjuvant hemiotheraphy we registered more intraoperative and early postoperative complications as: bleeding 10 vs. 7, changes in lung vessels (clinically manifested as rigid, with tendency to snap, when were dissected, and very difficult is to sowed with atraumatic pollen thread) 3 vs. 0, prolonged air leak 9 vs. 6, stump fistula (at pneumectomy patients) 2 vs. 0, pneumonia 9 vs. 3, wound infection 2 vs. 0, atelectasis 8 vs. 2, prolonged pleural drainage 10 vs. 4 (Fig. 1).
There, also, was no difference in 30 days mortality rate between groups. All this results were shown on Table 3.

**Discussion**

Radical anatomical resection of the lung (lobectomy or pneumectomy) for the early stage of NSCLC is method of choice in the treatment [1]. Unfortunately only 10 to 20% of patients with newly diagnosed lung carcinoma at the end become candidate for lung resection [2]. Reason for this are histological type (SCLC), advanced stage (high percent of patients in IIIA and IIIB stage), advanced age of patients and high percent of comorbidities (heart problems, respiratory insufficiency, kidney problems and so on).

Use of neoadjuvant chemotherapy made some of the cases operable, and later they were surgically treated. Pre-operative (neo-adjuvant) chemotherapy has shown promise in small trials restricted to stage IIIA patients [3-5]. In last time there were many studies to use neoadjuvant hemiotheraphy for IB, IIA and IIB stage also [6-12]. Many trials have shown that preoperative chemotherapy for lung cancer is feasible but associated with postoperative morbidity and mortality [3,11]. However, little is known about the effect of preoperative chemotherapy on surgical stress and postoperative complications associated with surgical intervention.

We very well know side effect of chemotherapy, which all are temporary, like: diarrhea, temporary hair loss, weight loss, fatigue, depression, nausea and vomiting, anemia. Also we know that is possible appearing heart failure, fatigue, problems with memory, appearing infertility, peripheral neuropathy, osteoporosis, problems with lung fibrosis, damage of kidney and bladder. But little is known about problems during surgery and after that. These side effects from the neoadjuvant chemotherapeutics are nearly always temporary. Most patients are able to continue with their normal activities for all but perhaps 1 or 2 days per month. Many of the side effect were treated with some medications, like metoclopramide (Reglan), ranitidine (Ranital), serotonin antagonists, especially ondansetron (Zofran), Filgrastim (Neupogen), entropoetin – epoetin alfa (Epogen), giving blood or some derivates from blood (plasma, trombocite mass), antibiotics and so on.

In literature there were many controversies about side effect during surgery and after that at patients with neoadjuvant hemiotheraphy. Authors like Boer, Sunsucke, Roberts, Albain, Venuta, say that in group with preoperative neoadjuvant chemotherapy there were register larger amount of complications, in some series they were statistically significant, and also in some series were detected larger amount of postoperative deaths [3-7]. On other hand authors like Siegenthaler, Perrot, Refai in their evaluations said that there were not significant complications in the group with neoadjuvant hemiotheraphy [8-10].

Chemotherapy induces both a transient and a relatively permanent immune deficit in treated patients. The most common cause of postoperative morbidity and mortality after lung resection is infectious, and complications after that, whether caused by pneumonia. It is reasonable to expect that neoadjuvant chemotherapy could affect the chances of postoperative morbidity and mortality. On the other hand lung resection is among the riskiest of surgical procedures, so it expected to be appeared more frequently complications.

In our examination we detected more complications in the group with preoperative neoadjuvant therapy. But no one complication is statistically significant more frequent in group with neoadjuvant hemiotheraphy. In our series we compare patient with lung cancer, preoperative treated only with hemiotheraphy (no radiotherapy). Some of the complication were minor and need only conservative treatment, mainly treatment of the infection. Treatment of the some complications need prolonged drainage, but at 3 were need reoperation.

Knowing that mainly complications were according disturbed immunity and according appearing infection of the lung, we obviously give two antibiotics per operatively and postoperatively, following parameters of inflammation (leukocyte number, CRP) and respond to that.

**Conclusion:** Neoadjuvant chemotherapy is giving for systematic treatment of lung cancer. Also at some patients there were detected down staging and is given chance for radical surgical treatment at patients.
where were not indicated at moment of diagnosis of lung cancer.

Complications were more frequent in the group with neoadjuvant hemiotheraphy and surgery, vs. group treated only surgically, but there were not statistically significances for any complication.

Strategies to prevent these complications will be important, especially if chemotherapy before resection becomes the standard for all patients with non–small cell lung cancer.

References